Express Scripts-Medco Specialty Pharmacy Combination Is Key To Merger, CEO Affirms
This article was originally published in The Pink Sheet Daily
Express Scripts would be unwilling to proceed with merger with Medco if FTC says the firm’s specialty drug division must be spun off, CEO George Paz tells Senate subcommittee.
You may also be interested in...
The FTC voted in a split 3-1 vote to close its investigation and allow Express Scripts’ $29.1 billion acquisition of rival PBM Medco to proceed.
Following the Federal Trade Commission’s second request for additional information about Express Scripts Inc.'s proposed acquisition of Medco Health Solutions Inc., it is now statistically likely that the deal will be blocked or subject to a divestiture.
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.